Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,764.40
(
-0.13%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
104.41
(
-0.02%
)
Bitcoin
70,458.00
(
0.80%
)
News Focus
News Focus
Post# of 30494
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Superfly15 post# 7212

Sunday, 06/16/2013 4:21:10 PM

Sunday, June 16, 2013 4:21:10 PM

Post# of 30494
MNTA has multiple shots on goal—generic Copaxone, FoB program, potential Lovenox-patent damages—and you’re paying almost nothing for them at the current valuation. Moreover, MNTA has ample cash* to last a long time, so you don’t have to worry about dilution.

*$344M as of 3/31/13 (including $20M of restricted cash).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now